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Abstract
This pharmacoepidemiologic study was conducted to
determine whether risk factors for upper gastrointestinal
bleeding influenced the prescription of cyclo-oxygenase (COX)-
2 inhibitors and traditional nonselective nonsteroidal anti-
inflammatory drugs (NSAIDs) at the time when COX-2 inhibitors
were first included in the formulary of reimbursed medications.
A population-based case–control study was conducted in
which the prevalence of risk factors and the medical histories of
patients prescribed COX-2 inhibitors and traditional
nonselective NSAIDs were compared. The study population
consisted of a random sample of members of the Quebec drug
plan (age 18 years or older) who received at least one
dispensation of celecoxib (n = 42,422; cases), rofecoxib (n =
25,674; cases), or traditional nonselective NSAIDs (n =
12,418; controls) during the year 2000. All study data were
obtained from the Quebec health care databases. Adjusting for
income level, Chronic Disease Score, prior use of low-dose
acetylsalicylic acid, acetaminophen, antidepressants,
benzodiazepines, prescriber specialty, and time period, the
following factors were significantly associated with the
prescription of COX-2 inhibitors: age 75 years or older (odds
ratio [OR] 4.22, 95% confidence interval [CI] 3.95–4.51), age
55–74 years (OR 3.23, 95% CI 3.06–3.40), female sex (OR
1.52, 95% CI 1.45–1.58), prior diagnosis of gastropathy (OR
1.21, 95% CI 1.08–1.36) and prior dispensation of
gastroprotective agents (OR 1.57, 95% CI 1.47–1.67). Patients
who received a traditional nonselective NSAID recently were
more likely to switch to a coxib, especially first-time users (OR
2.17, 95% CI 1.93–2.43). Associations were significantly
greater for celecoxib than rofecoxib for age, chronic NSAID use,
and last NSAID use between 1 and 3 months before the index
date. At the time of introduction of COX-2 inhibitors into the
formulary, prescription channeling could confound risk
comparisons across products.
Keywords: administrative health care databases, COX-2 inhibitors, nonsteroidal anti-inflammatory drugs, pharmacoepidemiology, prescription 
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Introduction
Although randomized clinical trials have confirmed the
advantage of cyclo-oxygenase (COX)-2 inhibitors over tra-
ditional nonselective nonsteroidal anti-inflammatory drugs
(NSAIDs) with respect to gastrotoxicity [1-8], a large
number of spontaneous reports have incriminated COX-2
inhibitors [9]. Numerous editorials and letters have been
published that question the safety of these products [10-
17]. The randomized clinical trial is the design best suited
to determine drug efficacy, but it is inadequate for the eval-
uation of effectiveness, which applies to heterogeneous
patient populations and patterns of drug use observed in a
real life setting. In addition to pharmacological differences
across products, the dosages used for the various indica-
tions [18] and past experience with the drug (through the
'depletion of susceptibles' effect) [19] account forR333ASA = acetylsalicylic acid; CDS = chronic disease score; COX = cyclo-oxygenase; NSAIDs = nonsteroidal anti-inflammatory drugs.
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tional setting, such as postmarketing surveillance, the deci-
sion to prescribe one product over another is influenced by
the characteristics of the patient, the prescriber and the
health care system [20]. In the absence of randomization, it
is consequently of utmost importance, when comparing the
risks associated with individual drug classes, to determine
whether the patient populations are indeed comparable.
The present study was conducted to compare the preva-
lence of selected risk factors for upper gastrointestinal
bleeding among patients prescribed COX-2 inhibitors with
those among patients prescribed traditional nonselective
NSAIDs, and to compare the characteristics of patients
prescribed celecoxib and rofecoxib, which are the two
COX-2 inhibitors marketed in Canada at the time of the
study.
Methods
Design
A case–control analysis was conducted in which the prev-
alence of selected gastrointestinal risk factors and medical
histories of patients prescribed COX-2 inhibitors (the
cases) were compared with those of users of traditional
nonselective NSAIDs (the controls).
Setting
The study involved prescriptions acquired through commu-
nity pharmacies by members of the Quebec public drug
program. Identification of eligible patients and acquisition
of study variables were conducted via linkage with four
administrative health care databases containing informa-
tion on beneficiaries, health professionals, pharmaceutical
services and medical services.
Study population
The study targeted all ambulatory adult residents (aged 18
years or older) of the province of Quebec who were mem-
bers of the public drug coverage program. In Quebec, cov-
erage of prescribed medications was universal for all
elderly residents (those aged 65 years or older) regardless
of income as well as for all welfare recipients. The program
was broadened in 1997 to include patients who do not
have access to a private insurance program regardless of
age. For everyone, the program now includes a deductible
payment and a co-payment, with a monthly premium that
depends on the beneficiary's income. In practice, the pro-
gram includes the following segments of the population:
the great majority of community-dwelling elderly persons
(>94%), welfare recipients and patients younger than 65
years who do not have access to private insurance (e.g. the
self-employed).
A sample of 100,000 drug plan members who received at
least one celecoxib or rofecoxib prescription between 1
January and 31 December 2000 was randomly selected. A
sample of 60,000 nonselective NSAID users was also ran-
domly selected during the same time period, and patients
who used low-dose aspirin (acetylsalicylic acid [ASA]
≤325 mg/day) only were excluded from the comparison
group. The study population included both new (incident)
users and longer time (prevalent) users. The status of
patients with respect to being a user of COX-2 inhibitor or
nonselective NSAID was determined at the end of the
study year. Patients who had received both a COX-2 inhib-
itor and a nonselective NSAID were considered to be
COX-2 inhibitor users. The index date was defined as the
date of first dispensation of a COX-2 inhibitor or, for the tra-
ditional nonselective NSAID group, the date of the first dis-
pensation of a nonselective NSAID.
The following inclusion criteria were applied: participants
were required to have been a resident of Quebec for at
least 2 years before the index date; and they were required
to have had continuous coverage of medical and pharma-
ceutical services for at least 2 years before the index date.
These criteria were verified through the beneficiary
database.
Study variables
The dependent variable was the prescription of COX-2
inhibitors (celecoxib or rofecoxib) or traditional nonselec-
tive NSAIDs. The independent variables were selected risk
factors for upper gastrointestinal bleeding: patient demo-
graphic characteristics (age, sex); prescribed dosage; con-
comitant use of corticosteroids or anticoagulants; history of
gastropathy (using four indicators: prior diagnosis of gas-
tropathy, history of upper gastrointestinal procedures, prior
dispensation of gastroprotective agents, and prior referral
to a gastroenterologist); and prior history of NSAID use.
Comparisons were controlled for prescriber specialty,
patient overall health status (using the Chronic Disease
Score [CDS]) [21], income level, past use use of low-dose
ASA, acetaminophen, antidepressants and benzodi-
azepines, and time period.
Risk factors for gastrointestinal events
Patient demographic characteristics included age, sex and
income level, which were sought from the beneficiary data-
base. For reasons of confidentiality, only age on 1 July
2000 was available. Income level was indirectly derived
from the type of coverage (amount of deductible payment
and co-payment), which was assigned to the patient based
on their income.
History of gastropathy was assessed during the year before
the index date through the presence of a diagnosis consist-
ent with upper gastrointestinal bleeding in the medical serv-
ices database. When present, this diagnosis was found to
be reliable [22]. However, because it is not mandatory for
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R335the physician to be reimbursed, it is often missing. Conse-
quently, three other markers were used: presence of an
upper gastrointestinal procedure (e.g. gastroscopy, radio-
logical examination) in the medical database; prior referral
to a gastroenterologist, using physician specialty in the
medical database; and prior dispensation of gastroprotec-
tive agents in the prescription database. Prescribed daily
dosage of the COX-2 inhibitors and the traditional nonse-
lective NSAIDs was derived from the dose per unit, quantity
dispensed and prescribed duration. Daily dosages were
subsequently categorized into low, standard and high, (for
each product the dosage thresholds are listed in Table 1).
Standard dosages were the recommended anti-inflamma-
tory dosages. The threshold for low-dose corresponded to
the maximum approved over-the-counter dosage, or, for
products available on perscription only, dosages below the
recommended prescribed anti-inflammatory dosage. High
dosages were those above the maximum recommended
anti-inflammatory dosage.
Details regarding the dispensation of acetaminophen, low-
dose ASA, corticosteroids (excluding asthma-related
drugs) and anticoagulants during the year before the index
date were obtained from the prescription database. Past
use of NSAIDs was assessed through records of the dis-
pensation of these agents during the year before the index
date. Patterns of use were defined using three categories
of recency (last dispensation ≤1 month, >1 to 3 months,
and >3 to 12 months before the index date). For recent
users, two categories of duration of use were obtained:
chronic (defined as at least one dispensation in each quar-
ter of the previous year) and nonchronic (defined as less
than one dispensation in each quarter).
Covariables
Other variables may influence the prescription of NSAIDs
and could act as confounders if they are also associated
with risk factors for gastrointestinal events. Patient overall
health status was assessed through records on medica-
tions dispensed during the year before the index date using
the CDS [21]. Scores are weighted according to the
number of different chronic diseases under treatment and
the severity of the diseases. The CDS has been found to
predict subsequent mortality and hospitalization rates.
Because health status at the index date was the variable
most likely to influence the physician's prescription, dis-
pensing data for the year before were used for the calcula-
tion. Based on the distribution of scores, four categories
were defined: 0, 1–4, 5–9 and ≥10. In addition, prescrip-
tions of antidepressants and benzodiazepines were also
considered to confirm the findings of a previous unpub-
lished study that demonstrated an association between
Table 1
Dosage categories for each product
Generic name Low dosage (mg/day) Standard dosage (mg/day) High dosage (mg/day)
Celecoxib ≤100a >100 to 200 >200
Rofecoxib <25 25 to <50 ≥50
Acetylsalicylic acid ≤1300 >1300 to <4000 ≥4000
Diclofenac (including Voltaren + Cytotec = Arthrotec) ≤50 >50 to 100 >100
Diflunisal ≤500 >500 to 1000 >1000
Etodolac ≤300 >300 to 900 >900
Fenoprofen <1800 1800 to 2400 >2400
Flurbiprofen ≤50 >50 to 200 >200
Ibuprofen <1000 1000 to 1200 >1200
Indomethacin ≤50 >50 to 100 >100
Ketoprofen ≤50 >50 to 200 >200
Mefenamic Acid <750 750 to 1000 >1000
Naproxen ≤550 >550 to 1100 >1100
Piroxicam ≤10 >10 to 20 >20
Salsalate ≤500 >500 to 1000 >1000
Tiaprofenic Acid ≤200 >200 to 600 >600
Tolmetin ≤600 >600 to 1200 >1200
aAccording to our references, 100 mg celecoxib would be considered a standard dose. However, because none of the patients were prescribed 
lower dosages, we included 100 mg as a low dose (in order to avoid a 0 cell).
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Characteristics of the study population
Traditional nonselective NSAIDs (n = 12,418) Celecoxib (n = 42,422) Rofecoxib (n = 25,674)
Age (years)
18–34 18.6 3.7 6.7
35–44 15.8 6.5 9.7
45–54 13.2 9.9 12.1
55–64 13.5 15.9 16.4
65–74 18.8 30.5 27.1
75–84 15.1 27.1 22.7
85+ 4.1 6.5 5.1
Sex
Female 55.4 67.4 65.5
Male 44.6 32.6 34.5
Income level
Low 14.8 10.9 11.4
Nonlow 85.2 89.1 88.6
Dosage category
High 11.6 31.2 8.8
Standard 66.3 65.3 73.0
Low 22.1 3.4 18.2
Prior diagnosis of gastropathy 3.6 7.7 5.0
Prior gastrointestinal procedures 2.0 4.5 2.7
Prior dispensation of gastroprotective agents 14.0 29.9 24.3
Prior referral to a gastroenterologist 2.8 6.0 3.9
History of NSAID use
Recent, first time 3.0 2.2 2.8
Recent, chronic 6.6 4.3 4.2
>1 to 3 months 15.7 7.8 6.3
>3 to 12 months 19.4 22.0 14.0
No use 55.2 63.7 72.8
Anticoagulants 1.3 3.3 3.0
Corticosteroids 11.7 19.6 16.9
Benzodiazepines 23.3 38.2 33.0
Antidepressants 10.5 17.2 15.7
Chronic Disease Score
≥10 5.2 10.3 8.2
5–9 19.6 28.6 25.4
1–4 27.9 33.6 32.6
0 47.3 27.6 33.8
Prescriber specialty
General practitioner 85.9 85.3 88.3
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COX-2 inhibitors. Prescriber specialty at the index date
was determined from the prescription database.
Index dates were categorized into three time periods during
the study year in order to account for differences in the date
of entry of COX-2 inhibitors into the formulary of reim-
bursed medications (July 1999 and April 2000 for
celecoxib and rofecoxib, respectively). The time periods
considered were January–June, July–September and Octo-
ber–December 2000.
Statistical analysis
The strength of the association between each patient char-
acteristic and prescribed drug class was measured using
odds ratios. The concomitant effect of patient characteris-
tics was examined using multivariate logistic regression.
Three models were used: COX-2 inhibitors as a class ver-
sus traditional nonselective NSAIDs, celecoxib versus tra-
ditional nonselective NSAIDs, and rofecoxib versus
traditional nonselective NSAIDs. All data were analyzed
using the SAS statistical package (SAS versions 6.12 and
8.0 for Windows; SAS Institute Inc., Cary, NC, USA). The
level of statistical significance was set at 0.05 and the sta-
tistical uncertainty of the estimates was assessed using
95% confidence intervals.
Ethical considerations
No patient or physician identifiers were provided to the
researchers; only scrambled identifiers were used through-
out the study. The study was approved by the Université de
Montréal Health Sciences Ethics Committee.
Results
After applying the selection criteria, 42,422 celecoxib,
25,674 rofecoxib and 12,418 traditional non-selective
NSAID users were identified for the study. The characteris-
tics of the study population are presented in Table 2.
Because of the very large sample size, all differences were
statistically significant and therefore P values are not
reported. Patients treated with celecoxib were on average
slightly older than those treated with rofecoxib or traditional
nonselective NSAIDs, and a larger proportion of women
were treated with COX-2 inhibitors as opposed to tradi-
tional nonselective NSAIDs. For each of the four indicators
of prior history of gastropathy, there was a larger proportion
of COX-2 inhibitor users with a positive history as com-
pared to nonselective NSAID users. For all indicators used,
the proportion was also greater for celecoxib than for
rofecoxib. Very few patients had used anticoagulants dur-
ing the year before the index date, but again the prevalence
of use was greater for COX-2 inhibitors than for traditional
nonselective NSAIDs.
Using the data presented in Table 2, we were able to deter-
mine that, overall, very few patients had used a nonselec-
tive NSAID for the first time during the month before the
index date. The proportion of patients who had received
their last NSAID prescription in the distant past (between 3
and 12 months before index date) was greater for celecoxib
than for rofecoxib. Of the patients treated with rofecoxib,
72.8% had not received any NSAIDs during the prior year,
which means that it was often used as a first treatment
obtained under prescription. This proportion was lower for
celecoxib (63.7%) and traditional nonselective NSAIDs
(55.2%). Only 6.3% of rofecoxib users had received their
last NSAID prescription between 1 and 3 months before
the index date, as compared with 7.8% among celecoxib
users and 15.7% among nonselective NSAID users.
The great majority of NSAIDs were prescribed by general
practitioners (85.9% of traditional nonselective NSAIDs,
85.3% of celebrex and 88.3% of rofecoxib prescriptions).
Dosage levels were highly heterogeneous across products.
A large proportion of traditional nonselective NSAIDs were
prescribed at dosages lower than those recommended for
anti-inflammatory indications (22.1%) in comparison with
celecoxib (3.4%) and rofecoxib (18.2%). Conversely, the
majority of COX-2 inhibitors were prescribed at standard
anti-inflammatory dosages (65.3% of celecoxib and 73.0%
of rofecoxib prescriptions). A relatively high proportion of
COX-2 inhibitors, especially celecoxib, were prescribed at
Cardiology 1.0 0.4 0.3
Internal Medicine 2.3 3.3 2.1
Neurology 0.3 0.3 0.2
General surgery 1.4 0.8 1.0
Obstetrics/gynaecology 1.5 0.2 0.3
Orthopaedic surgery 1.2 3.4 3.2
Rheumatology 2.5 2.5 1.7
Other 2.8 3.8 2.9
Values are expressed as percentages. NSAID, nonsteroidal anti-inflammatory drug.
Table 2 (Continued)
Characteristics of the study population
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Multivariate analysis of the factors associated with dispensation of selective COX-2 inhibitors versus traditional nonselective 
NSAIDs
Crude OR (95% CI) Adjusted OR (95% CI)
Age group (years)
75+ 3.17 (3.01–3.34) 4.22 (3.95–4.51)
55 to ≤74 2.86 (2.74–2.99) 3.23 (3.06–3.40)
18–54 Reference Reference
Female sex 1.61 (1.52–1.66) 1.52 (1.45–1.58)
Income level (lower) 0.72 (0.68–0.76) 0.90 (0.85–0.96)
Prior diagnosis of gastropathy 1.93 (1.75–2.11) 1.21 (1.08–1.36)
Prior gastrointestinal procedures 1.94 (1.71–2.22) 1.09 (0.94–1.27)
Prior dispensation of gastroprotective agents 2.37 (2.25–2.50) 1.57 (1.47–1.67)
Prior referral to gastroenterologist 1.89 (1.69–2.12) 1.23 (1.08–1.39)
Prior history of NSAID use
Recent, first time 2.39 (2.14–2.66) 2.17 (1.93–2.43)
Recent, chronic 1.58 (1.46–1.70) 1.21 (1.11–1.32)
>1 to 3 months 1.12 (1.06–1.19) 0.95 (0.89–1.01)
>3 to 12 months 0.93 (0.88–0.98) 0.84 (0.80–0.89)
No use in past year Reference Reference
Corticosteroids 1.72 (1.62–1.82) 1.16 (1.07–1.24)
Anticoagulants 2.53 (2.15–2.98) 1.56 (1.32–1.85)
Antidepressants 1.69 (1.59–1.80) 1.37 (1.28–1.46)
Benzodiazepines 1.87 (1.78–1.95) 1.20 (1.14–1.26)
Acetaminophen 1.85 (1.76–1.94) 1.41 (1.34–1.49)
Low dose ASA 0.85 (0.81–0.89) 0.56 (0.52–0.59)
Chronic Disease Score
10+ 2.88 (2.65–3.14) 1.26 (1.13–1.41)
5–9 2.21 (2.10–2.32) 1.28 (1.20–1.37)
1–4 1.88 (1.80–1.97) 1.26 (1.19–1.33)
0 Reference Reference
Specialist (versus GP) 0.99 (0.94–1.04) 0.89 (0.84–0.94)
Dosage
High dose 1.91 (1.80–2.03) 2.19 (2.06–2.33)
Low dose 0.40 (0.38–0.42) 0.29 (0.27–0.30)
Standard dose Reference Reference
Time period
January–June 0.72 (0.68–0.76) 0.54 (0.51–0.57)
July–Sept 1.02 (0.95–1.09) 0.99 (0.92–1.06)
October–December Reference Reference
All covariables included simultaneously in the models are listed in this table; models were not adjusted for any other factors. ASA, acetylsalicylic 
acid; CI, confidence interval; COX, cyclo-oxygenase; GP, general practitioner; NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio.
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Multivariate analysis of the factors associated with dispensation of celecoxib and rofecoxib versus traditional nonselective NSAIDs
Celecoxib Rofecoxib
Age group
75+ 5.34 (4.96–5.75) 3.06 (2.83–3.30)
55 to ≤74 3.65 (3.45–3.87) 2.62 (2.46–2.78)
18–54 Reference Reference
Female sex 1.55 (1.47–1.62) 1.45 (1.38–1.52)
Income level (lower) 0.95 (0.88–1.02) 0.83 (0.77–0.89)
Prior diagnosis of gastropathy 1.21 (1.07–1.37) 1.11 (0.97–1.27)
Prior gastrointestinal procedures 1.21 (1.02–1.42) 0.97 (0.81–1.16)
Prior dispensation of gastroprotective agents 1.59 (1.48–1.71) 1.51 (1.41–1.63)
Prior referral to gastroenterologist 1.27 (1.11–1.45) 1.19 (1.03–1.37)
Prior history of NSAID use:
Recent, first time 2.25 (1.99–2.54) 2.02 (1.79–2.29)
Recent, chronic 1.68 (1.52–1.85) 0.75 (0.68–0.84)
>1 to 3 months 1.36 (1.26–1.45) 0.48 (0.44–0.52)
>3 to 12 months 0.85 (0.80–0.91) 0.81 (0.76–0.87)
No use in past year Reference Reference
Corticosteroids 1.11 (1.02–1.20) 1.20 (1.11–1.31)
Anticoagulants 1.61 (1.34–1.94) 1.48 (1.23–1.78)
Antidepressants 1.38 (1.28–1.48) 1.37 (1.27–1.48)
Benzodiazepines 1.18 (1.12–1.25) 1.15 (1.09–1.22)
Acetaminophen 1.39 (1.31–1.48) 1.37 (1.28–1.45)
Low-dose ASA 0.67 (0.62–0.71) 0.58 (0.54–0.62)
Chronic Disease Score
10+ 1.26 (1.11–1.43) 1.20 (1.06–1.37)
5–9 1.28 (1.19–1.38) 1.23 (1.14–1.33)
1–4 1.25 (1.17–1.33) 1.26 (1.18–1.34)
0 Reference Reference
Physician specialty 0.96 (0.90–1.03) 0.83 (0.77–0.89)
Dosage
High dose 3.36 (3.15–3.58) 0.76 (0.70–0.82)
Low dose 0.09 (0.09–0.10) 0.73 (0.69–0.78)
Standard dose Reference Reference
Time period
January–June 1.25 (1.16–1.34) 0.24 (0.22–0.26)
July–September 1.09 (1.00–1.19) 0.93 (0.87–1.01)
October–December Reference Reference
ASA, acetylsalicylic acid; NSAID, nonsteroidal anti-inflammatory drug.
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of celecoxib and 8.8% of rofecoxib prescriptions). There
was a strong correlation between dosage and age. For all
products, the proportion of low dosages increased with
age, and conversely the proportion of high dosages
decreased with age (data not shown). This relationship was
also found for overall health status; the higher the CDS, the
higher was the proportion of prescriptions for low dosages
(30.4% of all prescriptions were of low dosages for
patients with a CDS 10+ versus 14.5% for those with a
CDS of 0).
Results of the multivariate logistic regression are presented
in Table 3. Increasing age and female sex were both asso-
ciated with greater likelihood of receiving a COX-2 inhibi-
tor. Compared with patients aged 18–54 years, older
patients were more likely to receive a COX-2 inhibitor, but
this association was greatly confounded by dosage cate-
gory. Income level marginally influenced the choice of prod-
uct; patients with lower income favoured the less costly
traditional nonselective NSAIDs. According to crude odds
ratio estimates, there was a positive association between
each indicator of history of gastropathy and the probability
of receiving a COX-2 inhibitor. However, when all the indi-
cators were fitted simultaneously in the multivariate model,
a history of gastrointestinal procedures was no longer sig-
nificant; this finding is probably attributable to correlation
between the various indicators. The analyses revealed an
association between the CDS scores and the probability of
receiving a COX-2 inhibitor, although no trend was
observed.
Use of acetaminophen, corticosteroids, anticoagulants,
antidepressants and benzodiazepines during the year
before the index date were all associated with the prescrip-
tion of COX-2 inhibitors. On the other hand, patients who
had received low-dose ASA during the previous year were
more likely to receive a traditional nonselective NSAIDs
than a COX-2 inhibitor. Specialists were less likely to pre-
scribe a COX-2 inhibitor than were general practitioners.
Results from the multivariate logistic regression models
specific for celecoxib and rofecoxib are presented in Table
4. As shown, the strength of the association with gastroin-
testinal risk factors was significantly greater for celecoxib
than for rofecoxib for age, past use of NSAIDs between 1
and 3 months before the index date, and recent chronic
NSAID use. Point estimates of odds ratio for sex, other pat-
terns of NSAID use, prior dispensation of gastroprotective
agents, prior referral to a gastroenterologist, prior
gastrointestinal procedures, prior use of antidepressants
and benzodiazepines, and anticoagulants were greater for
celecoxib than for rofecoxib, but the difference was not
significant.
Because rofecoxib was only included in the list of reim-
bursed medications in April 2000, it was not available for
half of the first time period, which explains its lower likeli-
hood of being prescribed than nonselective NSAIDs (odds
ratio 0.24, 95% confidence interval 0.22–0.26). However,
for the second period (July–Sept) there was no significant
difference between rofecoxib and celecoxib.
Discussion
This study provides empirical evidence that channeling
exists in the prescription of COX-2 inhibitors. Patients with
risk factors for gastropathy were more likely to receive a
COX-2 inhibitor than a traditional nonselective NSAID.
Age, sex and history of gastropathy are well known inde-
pendent risk factors for gastrointestinal bleeding, and it is
therefore not surprising that they influenced prescribing
practices. The effect of sex may be explained by greater
use of over-the-counter NSAIDs in the past, not recorded
in the databases, for the treatment of dysmenorrhoea. The
effect of corticosteroids and anticoagulants is also not sur-
prising, given that these drugs represent contraindications
to the prescription of traditional nonselective NSAIDs.
These findings are consistent with those obtained in a
recent study conducted in a UK primary care setting [23]
but they contradict those reported in a elderly Medicare
population in the USA [24]. In the latter study it appeared
that there was over-treatment with COX-2 inhibitors in
patients without risk factors, and under-treatment in
patients who had at least one risk factor. The effect of past
NSAID use is more difficult to interpret because of the lack
of data regarding reasons for discontinuation of NSAIDs.
Although past NSAID use has been found to be associated
with decreased incidence of gastrointestinal bleeding, the
impact that such a 'depletion of susceptibles' effect may
have on prescribing practices remains to be clarified.
Regardless of the underlying mechanism, it can be con-
cluded from these results that past NSAID use is likely to
confound risk comparisons across drug classes because it
is an independent risk factor for gastrointestinal problems
as well as influencing prescribing practices.
Patients who had received acetaminophen in the past were
more likely to switch to a COX-2 inhibitor than to a tradi-
tional nonselective NSAIDs. Patients who had received
antidepressants and benzodiazepines were also more likely
to receive a COX-2 inhibitor than a traditional nonselective
NSAID. This empirical finding is difficult to interpret. It may
be hypothesized that physicians may be more likely in gen-
eral to prescribe newer agents to patients who are anxious.
More studies are needed to explore further the interaction
between patients and physicians in order to elucidate this
issue.
Although there was an association between physician spe-
cialty and prescription of COX-2 inhibitors or traditional
Available online http://arthritis-research.com/content/7/2/R333
R341nonselective NSAIDs, the results did not confound the
associations between patient characteristics and prescrip-
tion practices.
Results for patient overall health status and prescribing
practices were highly confounded by dosage. This sug-
gests that, for the sickest patients, prescribing practices
are largely determined by dosage rather than by drug class.
Patients with a high level of comorbidity still receive
traditional nonselective NSAIDs but at lower dosages.
Such findings are likely to be time-sensitive because COX-
2 inhibitors were just introduced into the Canadian market
during the study period, and there might have been reluc-
tance in the medical community to prescribe newer agents
to sicker patients.
Comparisons between the two COX-2 inhibitors indicated
that for several risk factors under investigation the chan-
neling process is stronger for celecoxib than rofecoxib.
However, these findings should be interpreted with caution
because for several of the risk factors investigated the dif-
ferences between products were not statistically signifi-
cant. On the other hand, celecoxib was not always at a
disadvantage; past chronic NSAID use, which, according
to the depletion of susceptibles effect, places patients at a
lower risk for upper gastrointestinal events [19], was asso-
ciated with a greater probability of being prescribed
celecoxib than rofecoxib.
Many risk factors for gastrointestinal bleeding could not be
ascertained in this study, such as smoking status and alco-
hol use, which are known risk factors for gastrointestinal
events and have also been found to influence prescribing
practices [23]. Also, there were no data on indications but
we controlled for dosage, which, according to Griffin and
coworkers [18], is more likely to influence the risk of gas-
trointestinal bleeding than indication per se. Dosage had a
very large impact on the results, and its exclusion would
have produced spurious differences across products.
There were no data on over-the-counter use of NSAIDs
such as aspirin and ibuprofen. Therefore, it was not possi-
ble to explore the concomitant use of nonprescribed
NSAIDs. Finally, data are generalizable only to recent use
(in the previous year). We were not able to explore the
impact of more distant history. Nevertheless, the use of ret-
rospective data obtained from administrative databases
allowed us to examine the various associations in a truly
observational setting without influencing prescribing prac-
tices in any way. In addition, the large sample size allowed
us to conduct comparisons across individual products.
Conclusion
Our results provide empirical evidence that the introduction
of a new class of medications into the market results in the
channeling of patients at high risk for adverse effects.
However, as shown by the present study, differences
across individual products cannot be predicted from their
order of entry into the formulary. Other factors, such as mar-
keting strategies, play a major role as well. Neverthless, one
may conclude that selective prescribing results in a positive
association between risk factors and drug use, which could
confound risk comparisons across products.
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